Metformina + Sitagliptina Tecnigen

Metformin hydrochloride, the active ingredient in Metformina + Sitagliptina Tecnigen, is a Biguanide/DPP‑4 inhibitor presented as a tablet for oral use. It is employed to improve blood glucose control in adults with type 2 diabetes mellitus, often in combination with diet, exercise, and other antidiabetic agents.

GNH USA supplies Metformina + Sitagliptina Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance, and reliable logistics for global distribution.

Metformina + Sitagliptina Tecnigen is indicated for the management of type 2 diabetes mellitus, targeting hyperglycemia through complementary mechanisms.

- Type 2 diabetes mellitus: improves glycemic control as monotherapy or in combination with other oral antidiabetics. - Adjunct to diet and exercise: enhances the effect of lifestyle interventions in patients whose glucose levels remain elevated. - Combination therapy with insulin: provides additional glucose lowering when basal insulin alone is insufficient.

Metformina + Sitagliptina Tecnigen may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Abdominal discomfort - Headache - Upper respiratory tract infection - Mild hypoglycemia (when used with other glucose‑lowering agents)

Serious or Rare Side Effects: - Lactic acidosis - Severe hypoglycemia - Acute pancreatitis - Allergic reactions (rash, angioedema) - Hepatic dysfunction - Renal impairment

When prescribing Metformina + Sitagliptina Tecnigen, clinicians should consider several safety aspects.

- Renal function assessment: evaluate creatinine clearance before initiating therapy and periodically thereafter. - Hepatic impairment: use with caution in patients with liver disease. - Risk of lactic acidosis: avoid in conditions predisposing to hypoxia. - Pregnancy and lactation: safety not established; consider alternative therapy. - Drug interactions: review concomitant medications that affect renal clearance. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Metformina + Sitagliptina Tecnigen can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Concomitant use with intravenous contrast agents in patients with renal impairment. - Combination with other biguanides (e.g., phenformin). - Co‑administration with potent CYP2C8 inhibitors (e.g., gemfibrozil) that increase sitagliptin exposure. - Use with insulin secretagogues leading to severe hypoglycemia.

Moderate Interactions (Monitor Closely): - Concurrent diuretics may affect renal clearance of metformin. - Beta‑blockers may mask symptoms of hypoglycemia. - ACE inhibitors may increase risk of renal dysfunction. - Anticoagulants may require monitoring due to potential alteration in glycemic control.